Brazil Needs Better Orphan Drug Policies, Says Alexion
Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.
You may also be interested in...
Brazilian health ministry spending on medicines and treatment supplies acquired by patients taking legal action through the courts has rocketed from R$70m ($22.3) in 2008 to more than R$1bn ($317.9) in 2015, according to an audit by Brazil’s General Accounting Office (TCU).
A South American pricing coalition that includes Brazil, Venezuela and Argentina has announced plans to buy high-cost drugs, such as eculizumab (Alexion’s Soliris).
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.